The Patent Finder

Ogen GmbH

Also on record
Records under this name other than the patents Ogen GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.

Showing 1 to 6 of 6 · Back to Ogen GmbH

PatentTitleStatus Expires Confidence
US 9,758,581Humanized anti-CD4 antibody with immunosuppressive properties
Lapsed on the fee record
Ended Sep 12, 2025 · From the USPTO record
Lapsed on the fee recordEnded Sep 12, 2025From the USPTO record
US 8,586,715Humanized anti-CD4 antibody with immunosuppressive properties
Term ended
Term ended Aug 9, 2024 · From the USPTO record
Term endedTerm ended Aug 9, 2024From the USPTO record
US 8,440,806Humanized anti-CD4 antibody with immunosuppressive properties
Term ended
Term ended Jul 8, 2024 · From the USPTO record
Term endedTerm ended Jul 8, 2024From the USPTO record
US 7,452,981Humanized anti-CD4 antibody with immunosuppressive properties
Term ended
Term ended Mar 19, 2024 · From the USPTO record
Term endedTerm ended Mar 19, 2024From the USPTO record
US 8,673,304Humanized anti-CD4 antibody with immunosuppressive properties
Term ended
Term ended Mar 19, 2024 · From the USPTO record
Term endedTerm ended Mar 19, 2024From the USPTO record
US 8,685,651Method for screening for an anti-CD4 antibody suitable for use in immunotherapy
Lapsed on the fee record
Ended Apr 1, 2022 · From the USPTO record
Lapsed on the fee recordEnded Apr 1, 2022From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited